Aller au contenu principal
Profil bibliographique

Howard I. Schenker

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

7Publications signalées
512Citations signalées
0Affiliations récentes

Les domaines associés

Glaucoma and retinal disordersRetinal Diseases and TreatmentsCorneal surgery and disordersOcular Surface and Contact LensOphthalmology and Eye Disorders

Les publications récentes

Accès ouvert 2019 article OpenAlex

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients

Earl Randy Craven, Thomas R. Walters, William C. Christie, Douglas G. Day et autres

OBJECTIVE: The objective of this study was to evaluate the safety and intraocular pressure (IOP)-lowering effects over 24 months of biodegradable bimatoprost sustained-release implant (Bimatoprost SR) administration versus topical bimatoprost 0.03% in patients with open-angle glaucoma (OAG). METHODS: This was a phase …

us (code pays fourni par la source)

104 citations Drugs
Accès ouvert 2019 article OpenAlex

Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial

Sanjay Asrani, Alan Lee Robin, Janet B. Serle, Richard Alan Lewis et autres

PURPOSE: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination (FDC) of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost. DESIGN: Three-month primary endpoint analysis of a randomized, double-masked, phase 3 clinical trial. METHODS: …

us (code pays fourni par la source)

84 citations American Journal of Ophthalmology
Accès ouvert 2016 article OpenAlex

Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial

Richard Alan Lewis, William C. Christie, Marina Bejanian, Susan S. Lee et autres

PURPOSE: To evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR). DESIGN: Phase I/II, prospective, 24-month, dose-ranging, paired-eye controlled clinical trial. METHODS: At baseline following washout, open-angle glaucoma patients (n = 75) were administered Bimatoprost …

us, sa (code pays fourni par la source)

125 citations American Journal of Ophthalmology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.